IBM Hold Rating Ahead of Earnings as Growth Concerns Persist

What happened

Seeking Alpha rates IBM as a Hold due to possible overvaluation and tepid growth prospects, despite strategic initiatives in GenAI, quantum, and specialized semis. The master report shows Q2 2026 revenue rose only 1.1% to $17.162B, with Software up 5.1% but Infrastructure down 7.4% and IBM Z revenue plunging 42%. Recurring software revenue remains strong with $24.6B ARR and ~80% recurring, but transactional software lumpiness and client CAPEX shifts toward servers, storage, and memory caused significant deal slippage. The article echoes the market's 'prove it' narrative, emphasizing that recent earnings misses and revenue slowdowns have pressured the stock. Our WAIT rating is reinforced: the next 6-12 months hinge on whether delayed IBM Z and transaction-processing deals convert and whether AI demand shifts from consulting-heavy pipeline to higher-quality software growth.

Implication

Investors should remain cautious as valuation at 20.2x P/E and 16x EV/EBITDA already prices in a recovery that has not yet materialized. Key checkpoints include sequential improvement in IBM Z and Transaction Processing, Consulting revenue growth above 3%, and book-to-bill above 1.05. Until these metrics improve, the stock may stay range-bound between $210 and $255, with $210 offering a more favorable entry point given unresolved conversion risks. Failure to show progress in the next earnings report could trigger further downside, while disclosure of OpenAI-linked production deployments or signings acceleration would be a positive catalyst. We maintain a WAIT rating with a re-assessment window of 3-6 months.

Thesis delta

This article does not change our thesis; it reinforces the WAIT rating by highlighting overvaluation and tepid growth, consistent with our analysis. Our thesis remains that IBM offers durable cash flow and an enterprise moat, but near-term upside depends on proving deal conversion and AI software growth. The market's skepticism, as reflected in this Hold rating, could lead to further downside if upcoming earnings disappoint, but our base case already incorporates moderate improvement and a fair value around $235.